Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:58 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene
NCT05469178 · BerGenBio ASA · PHASE1/PHASE2 · terminated · last registry update 2025-10-29 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lack of efficacy” | Open Targets' class: negative | Registry record, BerGenBio ASA |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against AXL in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-05-26Also stopped (terminated): The University of Texas Health Science Center at San Antonio, bemcentinib + pacritinib (NCT06516887)
- 2026-05-14Also stopped (withdrawn): Sunshine Lake Pharma Co., Ltd., CT053PTSA (NCT04992858)
- 2025-09-25Results posted on the registry: BerGenBio ASA, Pembrolizumab + Bemcentinib (NCT03184571)
- 2025-02-26Results posted on the registry: BerGenBio ASA, Erlotinib + Bemcentinib (NCT02424617)
- 2025-01-29Results posted on the registry: BerGenBio ASA, Bemcentinib (NCT06469138)
- 2024-11-27Also stopped (terminated): Astellas Pharma Global Development, Inc., Gilteritinib + Erlotinib (NCT02495233)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision